Business Context and Reporting Period
This Form 8-K filing by BioXcel Therapeutics, Inc. (BTAI) reports on events occurring on July 3, 2026, with the report dated July 6, 2026. The filing details the entry into a "Tenth Amendment" to the Company's existing Credit Agreement and Guaranty with its lenders, led by Oaktree Fund Administration LLC.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring rather than operational financial performance. Key metrics disclosed include:
- Debt Payment Deferral: Principal originally due on June 30, 2026, is deferred to July 31, 2026.
- Payment Obligation: The Company is obligated to pay $9,016,914.47 (principal and interest due as of June 30, 2026) plus accrued interest and fees through July 31, 2026.
- Interest Capitalization: Accrued and unpaid interest through June 30, 2026, is being paid in kind (PIK) by adding it to the outstanding principal.
- Amendment Fee: A fee of 100 basis points (1.00%) of the outstanding principal was paid in kind by capitalizing the amount into the loan principal.
- Liquidity Covenant: The minimum cash liquidity requirement was reduced from $12.5 million to $7.5 million.
Material Changes and Covenants
The Tenth Amendment introduces significant operational and financial restrictions compared to the prior agreement:
- Transaction Requirement: The Company must enter into definitive agreements by July 31, 2026, for a transaction acceptable to lenders that either repays all obligations or provides alternative capital solutions.
- Strategic Process Committee: A new committee, comprised solely of David Mack (and/or an independent director acceptable to lenders), has exclusive authority to evaluate and implement sales, restructurings, equity raises, or bankruptcy filings.
- Reporting and Budgeting: The Company must hold weekly meetings with lenders and provide a 13-week cash flow budget and bi-weekly financial reports. Disbursements are capped at 115% of the budgeted amount for any two-week period.
- Restrictions: New negative covenants prohibit dividends, equity repurchases, new investments, asset disposals, new indebtedness, and modifications to material contracts. Compensation arrangements for directors and officers are frozen through July 31, 2026.
- Assignment Rights: Lenders are permitted to transfer or assign their loans to third parties without restriction.
Outlook, Risks, and Management Commentary
The filing indicates a critical juncture for the Company's solvency and capital structure. The requirement to secure a definitive transaction by July 31, 2026, suggests an imminent need for refinancing, a sale, or a restructuring to avoid default. The establishment of a special committee with authority over potential bankruptcy or insolvency filings highlights the severity of the liquidity situation. The filing does not provide specific forward-looking revenue guidance or management commentary on operational milestones, focusing entirely on the debt agreement terms.
Investor Verification Checklist
- Verify the total outstanding principal amount of the loans as of July 3, 2026, to calculate the exact impact of the 1% PIK fee and capitalized interest.
- Confirm the Company's current cash balance to assess compliance with the new $7.5 million minimum liquidity covenant.
- Monitor for announcements regarding the "definitive agreements" required by July 31, 2026, to determine if the Company will meet its repayment or restructuring obligations.
- Review the composition and actions of the newly formed Strategic Process Committee led by David Mack.
- Check for any subsequent filings regarding the assignment of loans to third-party lenders.